Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against non-alcoholic fatty liver disease
CONCLUSIONS: Ursolic acid could improve immune inflammation in NAFLD by modulating SPP1-mediated Th17 cell differentiation via the ERK signaling pathway, which is orchestrated jointly by ITGB1 and CD44, emerging as a linchpin in this molecular cascade.PMID:38623614 | DOI:10.3350/cmh.2024.0047 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 16, 2024 Category: Gastroenterology Authors: Yiyuan Zheng Lina Zhao Zhekun Xiong Chaoyuan Huang Qiuhong Yong Dan Fang Yugang Fu Simin Gu Chong Chen Jiacheng Li Yingying Zhu Jing Liu Fengbin Liu Yong Li Source Type: research
Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis
CONCLUSION: MAFLD is common as a sole aetiology, but more so and as a co-factor in mixed-aetiology HCC, supporting the use of a positive diagnostic criteria.PMID:38623613 | DOI:10.3350/cmh.2024.0109 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 16, 2024 Category: Gastroenterology Authors: Harry Crane Guy D Eslick Cameron Gofton Anjiya Shaikh George Cholankeril Mark Cheah Jian-Hong Zhong Gianluca Svegliati-Baroni Alessandro Vitale Beom Kyung Kim Sang Hoon Ahn Mi Na Kim Simone Strasser Jacob George Source Type: research
Overexpression of Slc22a18 facilitates fat accumulation in mice
Biochem Biophys Res Commun. 2024 Apr 9;712-713:149922. doi: 10.1016/j.bbrc.2024.149922. Online ahead of print.ABSTRACTWe previously reported that solute carrier family 22 member 18 (Slc22a18) regulates lipid accumulation in 3T3-L1 adipocytes. Here, we provide additional evidence derived from experiments with adenoviral vector expression and genetic manipulation of mice. In primary cultured rat hepatocytes, adenoviral overexpression of mouse Slc22a18 increased triglyceride accumulation and triglyceride synthetic activity, which was decreased in an adenoviral knockdown experiment. Adenoviral overexpression of mouse Slc22a18 ...
Source: Biochemical and Biophysical Research communications - April 16, 2024 Category: Biochemistry Authors: Takashi Yamamoto Yoko Iizuka Kozue Izumi-Yamamoto Midori Shirota Nobuko Mori Yoshikazu Tahara Toshiro Fujita Takanari Gotoda Source Type: research
Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against non-alcoholic fatty liver disease
CONCLUSIONS: Ursolic acid could improve immune inflammation in NAFLD by modulating SPP1-mediated Th17 cell differentiation via the ERK signaling pathway, which is orchestrated jointly by ITGB1 and CD44, emerging as a linchpin in this molecular cascade.PMID:38623614 | DOI:10.3350/cmh.2024.0047 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 16, 2024 Category: Gastroenterology Authors: Yiyuan Zheng Lina Zhao Zhekun Xiong Chaoyuan Huang Qiuhong Yong Dan Fang Yugang Fu Simin Gu Chong Chen Jiacheng Li Yingying Zhu Jing Liu Fengbin Liu Yong Li Source Type: research
Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis
CONCLUSION: MAFLD is common as a sole aetiology, but more so and as a co-factor in mixed-aetiology HCC, supporting the use of a positive diagnostic criteria.PMID:38623613 | DOI:10.3350/cmh.2024.0109 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 16, 2024 Category: Gastroenterology Authors: Harry Crane Guy D Eslick Cameron Gofton Anjiya Shaikh George Cholankeril Mark Cheah Jian-Hong Zhong Gianluca Svegliati-Baroni Alessandro Vitale Beom Kyung Kim Sang Hoon Ahn Mi Na Kim Simone Strasser Jacob George Source Type: research
Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients
Volume 40, Issue 1, December 2024 . (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - April 16, 2024 Category: Endocrinology Authors: Alessandro D. GenazzaniChristian BattipagliaLaura RusceGreta PrampoliniClaudia AioFrancesco RicciardielloMartina FoschiAlessandra SponzilliElisa SempriniTabatha PetrilloGynecological Endocrinology Center, Department of Obstetrics and Gynecology, Universit Source Type: research
Incretin-based investigational therapies for the treatment of MASLD/MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common form of chronic liver disease. It exists as either simple steatosis or its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), formerly, non-alcoholic steatohepatitis (NASH). The global prevalence of MASLD is estimated to be 32% among adults and is projected to continue to rise with increasing rates of obesity, type 2 diabetes, and metabolic syndrome. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 16, 2024 Category: Endocrinology Authors: Bram Brouwers, Girish Rao, Yuanyuan Tang, Ángel Rodríguez, Leonard C Glass, Mark L Hartman Source Type: research
Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
ConclusionsThe quantitative measurement system for M2BPGi depends on liver fibrosis and inflammation, regardless of etiology. Liver inflammation complicates the interpretation of M2BPGi-Qt results when assessing the fibrosis stage. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - April 16, 2024 Category: Gastroenterology Source Type: research
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
World J Gastroenterol. 2024 Mar 21;30(11):1480-1487. doi: 10.3748/wjg.v30.i11.1480.ABSTRACTDuring the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular interest rose regarding the interaction between metabolic dysfunction-associated fatty liver disease (MAFLD) and the COVID-19 infection. Several studies highlighted the fact that individuals with MAFLD had higher probability of severe acute respiratory syndrome coronavirus 2 infection and more severe adverse clinical outcomes. One of the proposed mechanisms is the inflammatory response pathway, especially the one involving cytokines, such as interleuk...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Leonidas Brilakis Eirini Theofilogiannakou Panagis M Lykoudis Source Type: research
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
World J Gastroenterol. 2024 Mar 21;30(11):1480-1487. doi: 10.3748/wjg.v30.i11.1480.ABSTRACTDuring the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular interest rose regarding the interaction between metabolic dysfunction-associated fatty liver disease (MAFLD) and the COVID-19 infection. Several studies highlighted the fact that individuals with MAFLD had higher probability of severe acute respiratory syndrome coronavirus 2 infection and more severe adverse clinical outcomes. One of the proposed mechanisms is the inflammatory response pathway, especially the one involving cytokines, such as interleuk...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Leonidas Brilakis Eirini Theofilogiannakou Panagis M Lykoudis Source Type: research
Gastroenterology/Hepatology: What You May Have Missed in 2023
This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding. The authors feature a randomized trial about amitriptyline as treatment for pat...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Sama Anvari Kayla Dadgar Ciar án Galts Michael Bretthauer Source Type: research
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
World J Gastroenterol. 2024 Mar 21;30(11):1480-1487. doi: 10.3748/wjg.v30.i11.1480.ABSTRACTDuring the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular interest rose regarding the interaction between metabolic dysfunction-associated fatty liver disease (MAFLD) and the COVID-19 infection. Several studies highlighted the fact that individuals with MAFLD had higher probability of severe acute respiratory syndrome coronavirus 2 infection and more severe adverse clinical outcomes. One of the proposed mechanisms is the inflammatory response pathway, especially the one involving cytokines, such as interleuk...
Source: World Journal of Gastroenterology : WJG - April 15, 2024 Category: Gastroenterology Authors: Leonidas Brilakis Eirini Theofilogiannakou Panagis M Lykoudis Source Type: research
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
World J Gastroenterol. 2024 Mar 21;30(11):1480-1487. doi: 10.3748/wjg.v30.i11.1480.ABSTRACTDuring the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular interest rose regarding the interaction between metabolic dysfunction-associated fatty liver disease (MAFLD) and the COVID-19 infection. Several studies highlighted the fact that individuals with MAFLD had higher probability of severe acute respiratory syndrome coronavirus 2 infection and more severe adverse clinical outcomes. One of the proposed mechanisms is the inflammatory response pathway, especially the one involving cytokines, such as interleuk...
Source: World Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Authors: Leonidas Brilakis Eirini Theofilogiannakou Panagis M Lykoudis Source Type: research
Gastroenterology/Hepatology: What You May Have Missed in 2023
This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding. The authors feature a randomized trial about amitriptyline as treatment for pat...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Sama Anvari Kayla Dadgar Ciar án Galts Michael Bretthauer Source Type: research
